|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
|
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Current asset - cash | ||||||||
| Prepaid expenses | ||||||||
| Deferred offering costs | ||||||||
| Total current assets | ||||||||
| Prepaid expenses, non-current | ||||||||
| Cash and marketable securities held in Trust Account | ||||||||
| Total Assets | ||||||||
| Liabilities, Redeemable Common Stock and Stockholders’ Deficit | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued expenses | ||||||||
| Promissory note – related party | ||||||||
| Income taxes payable | ||||||||
| Accrued franchise tax | ||||||||
| Due to related party | ||||||||
| Sponsor IPO Loan | ||||||||
| Working Capital Notes | ||||||||
| Accrued professional fees | ||||||||
| Total current liabilities | ||||||||
| Warrant liabilities | ||||||||
| Deferred legal and professional fee | ||||||||
| Deferred underwriting discount | ||||||||
| Total liabilities | ||||||||
| Redeemable Common Stock | ||||||||
| Class A common stock subject to possible redemption, 28,750,000 shares at redemption value | ||||||||
| Stockholders’ Deficit: | ||||||||
| Class A common stock, $0.0001 par value; 320,000,000 shares authorized; | ||||||||
| Class B common stock | ||||||||
| Total class A common stock, $0.0001 par value; 320,000,000 shares authorized; | ||||||||
| Class B common stock, $0.0001 par value; 20,000,000 shares authorized; 7,187,500 shares issued and outstanding | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ||||||||
| Stockholders’ deficit | ||||||||
| Class A common stock | ||||||||
| Class B common stock | ||||||||
| Total stockholders’ deficit | ||||||||
| Total Liabilities, Redeemable Common Stock and Stockholders’ Deficit |
Loading...
